Abstract
Objectives. To determine the clinical profile and treatment outcomes of patients with Stenotrophomonas maltophilia pneumonia admitted to the University of the Philippines – Philippine General Hospital (UP-PGH)
Methodology. We reviewed the medical and laboratory records of patients with Stenotrophomonas maltophiliapneumonia who were admitted to the UP-PGH from January 2019 to December 2022.
Results. A total of 265 patients (50.6% males, median age of 59 years) with S. maltophilia pneumonia were included. Forty-five percent were admitted to the service ward, and 43% were admitted to the ICU. Most patients were ventilator-associated (67.2%). Only three cases were community-acquired. Sixty-four percent of S. maltophilia pneumonia cases were monomicrobial. K. pneumoniae and A. baumannii were the most common isolates in patients with polymicrobial pneumonia. Septic shock was present in 41.5% of the patients. In vitro susceptibility to levofloxacin (90.6%) and minocycline (85.7%) was greater than that to TMP-SMX (75.8%). Most patients received targeted therapy consisting of TMP-SMX monotherapy. In two-thirds of the patients, the duration of antibiotic therapy ranged from 7 to 14 days. The overall mortality rate was 45.3%, with 60.8% attributed to S. maltophilia infection.
Conclusion. S. maltophilia pneumonia was common among patients with comorbidities who were on prolonged hospitalization and on mechanical ventilation. It was associated with a high mortality rate.